Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the sector will be on Bristol-Myers Squibb (NYSE: BMY ) , Merck (NYSE: MRK ) , and Pfizer (NYSE: PFE ) to see how these companies are overcoming patent expirations, declining sales, and pipeline development to keep investors profiting in the long term. A key part of that profit is, of course, their strong dividend payouts -- Bristol yields 2.8%, Merck 3.0%, and Pfizer 3.4%.
Each of these three big pharma giants has dealt with tough patent blows, from Pfizer's loss of blockbuster drug Lipitor's exclusivity to Bristol's struggles since it lost patent protection on former star therapy Plavix. However, new drugs are rising to build foundations at these companies, from Merck's diabetes duo of Januvia and Janumet to Bristol and Pfizer's big-potential blood thinner Eliquis, which has struggled to a slow start out of the gate so far in its young life.
Can these pharmaceutical titans pass a clean bill of health this earnings season? Find out in the video below, where Motley Fool contributor Dan Carroll shows you what you need to watch for in each of these three companies' earnings results -- and whether these stocks can mount a rally through 2014.
9 more dividend stocks investors love
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.